Corrects EPS in Key Details table to $0.17, from $0.19
Overview
Biopharmaceutical firm's Q4 revenue up, driven by ARCALYST sales growth
Net income for Q4 was $14.2 mln, reversing a loss from last year
Company expects 2026 ARCALYST revenue between $900 mln and $920 mln
Outlook
Kiniksa expects 2026 ARCALYST net product revenue of $900 mln to $920 mln
Company expects KPL-387 Phase 2 data in second half of 2026
Kiniksa plans to initiate KPL-1161 Phase 1 trial by end of 2026
Result Drivers
ARCALYST SALES GROWTH - Significant growth in ARCALYST sales due to its adoption as a preferred treatment for recurrent pericarditis, contributing to a 62% year-over-year increase
CASH RESERVES - Cash balance increased by $170.4 mln in 2025, supporting further investments in pipeline
CLINICAL PIPELINE - Initiation of KPL-387 Phase 2/3 program and planned Phase 1 trial for KPL-1161 to expand treatment options
Company press release: ID:nGNX3hxSm1
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Revenue | $202.13 mln | ||
Q4 EPS | $0.17 | ||
Q4 Net Income | $14.20 mln | ||
Q4 Operating Expenses | $182.36 mln | ||
Q4 Pretax Profit | $23.27 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $56.50, about 19.2% above its February 23 closing price of $47.39
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 24 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments